## MCK: McKesson Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.4% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($799.78)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. McKesson (MCK) Gets Higher Target at Deutsche Bank Despite Planned Spin-Off**
- Source: Finviz | 20251231T010833 | Bullish | Relevance: 100%
- Deutsche Bank analyst George Hill raised the price target on McKesson Corporation (NYSE:MCK) to $904 from $861, reiterating a Buy rating, despite the planned spin-off of its med-surgical business by the end of 2027. The company's fiscal 2026 profit forecast was raised earlier in November due to strong oncology and specialty drug distribution. Although revenue slightly missed expectations in the most recent quarter, the company's adjusted EPS significantly beat estimates.

**2. Is It Worth Investing in McKesson (MCK) Based on Wall Street's Bullish Views?**
- Source: Finviz | 20251230T160820 | Neutral | Relevance: 100%
- This article analyzes McKesson (MCK) stock, referencing its average brokerage recommendation (ABR) of 1.47, indicating a Strong Buy to Buy consensus among 17 brokerage firms. However, it cautions against solely relying on ABRs due to potential bias, recommending the Zacks Rank as a more reliable tool for predicting stock price movements, which currently rates MCK as a Zacks Rank #3 (Hold).

**3. McKesson Corporation: Quiet Rally, Strong Fundamentals – Is This Healthcare Giant Still Underprice**
- Source: AD HOC NEWS | 20251230T002336 | Bullish | Relevance: 100%
- McKesson Corporation has seen a quiet but resilient uptrend, with its stock hovering near record highs and outperforming major indices over the past year. Driven by strong cash flows, aggressive share buybacks, and steady pharmaceutical distribution contracts, the company exhibits the predictability defensive investors seek. While analysts are broadly constructive and see it as a high-quality core holding, questions remain about how much upside is left after significant gains.

**4. McKesson Corporation: Quiet Rally, Strong Fundamentals – Is This Healthcare Giant Still Underprice**
- Source: AD HOC NEWS | 20251230T000829 | Bullish | Relevance: 100%
- McKesson Corporation's stock has shown a resilient uptrend, nearing its 52-week high, driven by strong cash flows, aggressive share buybacks, and steady pharma distribution contracts. Despite its impressive performance over the past year, questions remain about how much upside is left, and whether it still represents a value play or has become a fully priced compounded asset. Wall Street analysts maintain a constructive outlook, viewing McKesson as a high-quality core holding with moderate future upside.

**5. McKesson (MCK) Gets Higher Target at Deutsche Bank Despite Planned Spin-Off**
- Source: Insider Monkey | 20251230T230203 | Bullish | Relevance: 100%
- Deutsche Bank analyst George Hill raised the price target for McKesson Corporation (MCK) to $904 from $861, maintaining a Buy rating despite the company's plan to spin off its med-surgical business by the end of 2027. This positive outlook is supported by McKesson's raised fiscal 2026 profit forecast, driven by strong growth in oncology and specialty drug distribution, which offer higher margins. The company's recent financial results also exceeded profit estimates, although revenue was slightly below expectations.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $960 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 1 ($0.28M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.8% (-0.3%)
- Blackrock Inc.: 9.2% (+0.4%)
- State Street Corpora: 4.7% (+0.9%)
- JPMORGAN CHASE & CO: 4.5% (+16.0%)
- Massachusetts Financ: 3.2% (-1.5%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.00 indicates undervaluation relative to growth. Balance sheet: $2.3B free cash flow. Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $102.9B |
| Beta | 0.38 |
| 52W Range | $565.75 - $895.58 |
| Short Interest | 1.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.00 |
| Forward P/E | 18.9 |
| Current P/E | 21.4 |
| YoY Growth | 13.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 stable at 0.4% (minimal 5-day change). Below STRENGTH zone by 2.6pp (needs >3.0% for momentum thesis). MRS_5 at 0.4% confirms short-term momentum alignment. MACD histogram positive (1.59), confirming momentum. RSI neutral at 52. OFD pattern: -MTL (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.39% (CS: 71) | Neutral |
| RSI_14 | 51.7 | Neutral |
| MACD Histogram | 1.59 | Bullish |
| vs SMA20 | 1.014x | Above |
| vs SMA50 | 0.997x | Below |
| vs SMA200 | 1.121x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $827.02
- **Stop Loss:** $799.78 (3.3% risk)
- **Target:** $854.26 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 48
- **Position Value:** $39,696.96
- **Portfolio %:** 39.70%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with balanced risk signals and moderate market participation. VIX at 14.33 indicates calm conditions, while positive yield curve (+59bps) and stable economic data support continued expansion. Year-end positioning and Fed uncertainty create near-term caution, but no systemic risks evident.*

### Earnings

**Next:** 2026-02-04 (Est: $9.28)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $9.05 | $9.86 | +8.9% |
| 2025Q2 | $8.15 | $8.26 | +1.4% |
| 2025Q1 | $9.83 | $10.12 | +3.0% |
| 2024Q4 | $7.99 | $8.03 | +0.5% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*